Home › Myelodysplastic Syndromes
Pag-aaral pangklinika para sa Myelodysplastic Syndromes na nagre-recruit sa U.S.
158 pag-aaral para sa Myelodysplastic Syndromes ang nagre-recruit ng mga kalahok sa mga site sa buong Estados Unidos.
Mga lungsod na may pinakamaraming pag-aaral
- Houston, TX43 pag-aaral
- Baldwin Park, CA27 pag-aaral
- New York City, NY22 pag-aaral
- Seattle, WA21 pag-aaral
- Boston, MA20 pag-aaral
- Tampa, FL20 pag-aaral
- Washington, DC19 pag-aaral
- Miami, FL17 pag-aaral
- Durham, NC14 pag-aaral
- Columbus, OH14 pag-aaral
- Atlanta, GA13 pag-aaral
- Chicago, IL13 pag-aaral
- St. Louis, MO13 pag-aaral
- Nashville, TN11 pag-aaral
- Cleveland, OH11 pag-aaral
- Philadelphia, PA10 pag-aaral
- Los Angeles, CA10 pag-aaral
- Birmingham, AL10 pag-aaral
- Jacksonville, FL10 pag-aaral
- The Bronx, NY9 pag-aaral
- Buffalo, NY9 pag-aaral
- Winston-Salem, NC9 pag-aaral
- Mountain View, CA9 pag-aaral
- Pittsburgh, PA9 pag-aaral
- Baltimore, MD9 pag-aaral
- New Haven, CT8 pag-aaral
- Milwaukee, WI8 pag-aaral
- Portland, OR8 pag-aaral
- Rochester, MN8 pag-aaral
- Minneapolis, MN8 pag-aaral
- Salt Lake City, UT8 pag-aaral
- Orange, CA7 pag-aaral
- Dallas, TX7 pag-aaral
- Clifton, NJ7 pag-aaral
- Rochester, NY7 pag-aaral
- Kansas City, MO7 pag-aaral
- Memphis, TN7 pag-aaral
- Aurora, CO7 pag-aaral
- Cedar Rapids, IA7 pag-aaral
- Edison, NJ7 pag-aaral
Ayos sa estado
- Alabama10 pag-aaral
- Arizona11 pag-aaral
- Arkansas4 pag-aaral
- California41 pag-aaral
- Colorado9 pag-aaral
- Connecticut10 pag-aaral
- District of Columbia4 pag-aaral
- Florida32 pag-aaral
- Georgia15 pag-aaral
- Hawaii3 pag-aaral
- Idaho5 pag-aaral
- Illinois17 pag-aaral
- Indiana4 pag-aaral
- Iowa7 pag-aaral
- Kansas5 pag-aaral
- Kentucky5 pag-aaral
- Louisiana6 pag-aaral
- Maine4 pag-aaral
- Maryland23 pag-aaral
- Massachusetts22 pag-aaral
- Michigan9 pag-aaral
- Minnesota15 pag-aaral
- Mississippi3 pag-aaral
- Missouri15 pag-aaral
- Montana3 pag-aaral
- Nebraska4 pag-aaral
- New Hampshire5 pag-aaral
- New Jersey13 pag-aaral
- New Mexico4 pag-aaral
- New York38 pag-aaral
- North Carolina19 pag-aaral
- North Dakota5 pag-aaral
- Ohio22 pag-aaral
- Oklahoma4 pag-aaral
- Oregon10 pag-aaral
- Pennsylvania17 pag-aaral
- Rhode Island4 pag-aaral
- South Carolina7 pag-aaral
- Tennessee15 pag-aaral
- Texas44 pag-aaral
- Utah8 pag-aaral
- Vermont3 pag-aaral
- Virginia8 pag-aaral
- Washington22 pag-aaral
- West Virginia4 pag-aaral
- Wisconsin12 pag-aaral
Mga pag-aaral na kamakailan lamang in-update
Opisyal na teksto ng pag-aaral (English)
Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders
Nagre-recruitObservasyonal na pag-aaral
1 Day – 99 Years · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT07683104Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Nagre-recruitPhase 1/2
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Nob 13, 2026 · NCT06303193Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
Nagre-recruitPhase 1
Edad 21 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07737769Allogeneic iNKT Cell Therapy (agenT-797) After SCT
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT07758218Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT02115295Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Nagre-recruitPhase 2
Edad 4 hanggang 80 · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01174108Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 12, 2026 · NCT01311258Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT04986657Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
Nagre-recruitPhase 1
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Nob 9, 2026 · NCT06996119A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT06499285HPC Offered for PRESERVE Expansion
Nagre-recruitObservasyonal na pag-aaral
Edad 12 hanggang 80 · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07145411Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS)
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT05308264A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Lower Risk Myelodysplastic Syndromes (LR-MDS) Who Need Regular Blood Transfusions
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07422480At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT05969860Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06577441Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT06484062Personalized NK Cell Therapy in CBT
Nagre-recruitPhase 2
Edad 15 hanggang 80 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT02727803MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT05564390Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Nagre-recruitPhase 1
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Nob 2, 2026 · NCT06904066225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
Nagre-recruitPhase 1
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06287944Mosaic Trial for Stem Cell Transplant Recipients
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06960993Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06265584Study of REM-422 in Patients With AML or Higher Risk MDS
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT06297941Prophylactic DLI-X for Leukemia Relapse After HCT
Nagre-recruitPhase 1
Hanggang edad 65 · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT07254793Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 29, 2026 · NCT02333604Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.